Skip to content
Organo-ID logo — Preclinical Disease Models via Organoid technologies

Organo-ID

Preclinical Disease Models via Organoid technologies

Founded 2020 Turkey Turkey 7 employees Convertible Note Total: $200.00K Biotechnology, Health Care

General Information

Company Name Organo-ID
Founded Year 2020
Location Turkey Turkey
Founders / Decision Makers
Team member
Employees 7
Industries Biotechnology, Health Care
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with Organo-ID. To contact Organo-ID, visit organo-id.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Organo-ID compare?

A PDF of Organo-ID and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Organo-ID soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Organo-ID

Organo-ID is a biotechnology startup based in Turkey, founded in 2020. The company specializes in creating pre-clinical in vitro disease models through the utilization of organoid technologies, with a particular focus on human cancer and liver pathologies. Their mission is to revolutionize the understanding and treatment of these diseases. Most notably, their recent funding round of $100.00KConvertible Note was secured on 06 July 2022 from Idacapital, reflecting growing investor interest in their innovative approach. Organo-ID's dedication to cutting-edge technologies and its potential impact in the health care industry makes it a compelling prospect for venture capital investment.

Business keywords: Preclinical Disease Models, In vitro disease models, Organoid technologies, Human cancer, Liver pathologies, Metabolic liver disease, Rare diseases, Cancer treatment response testing, Personalized oncology, 3D cell culture, iPSC, Stem cell expertise

Services & Products

development of pre-clinical disease models
organoid technology commercialization
personalized drug testing services

Target Customers

Pharmaceutical companies research institutions oncologists precision medicine centers biobanks

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note Organo $100.00K 1
Idacapital
06 Jul 2022
Pre Seed Round Organo $100.00K 1
Idacapital
16 Aug 2020

Organo-ID Alternatives & Competitors

View All Alternatives
Organo-ID vs
Emulate, Inc.
Emulate, Inc. United States

Our Organ-on-a-Chip technology provides a high-fidelity window into the inner workings of human biol...

Series F
71 employees
Biotechnology, Health Care
Organo-ID vs

The Newcells ophthalmology business was acquired by Axol Bioscience

12 employees
Biotechnology, Health Care
Organo-ID vs

Developing new treatments for rare metabolic disorders

Debt Financing
27 employees
Biotechnology, Health Care

FAQ About Organo-ID

Preclinical Disease Models via Organoid technologies
Organo-ID was founded in 2020.
Organo-ID is headquartered in Turkey.
Organo-ID operates in Biotechnology and Health Care. Its work centres on Preclinical Disease Models, In vitro disease models, Organoid technologies and Human cancer. Its customers include Pharmaceutical companies, research institutions and oncologists.
Organo-ID has approximately 7 employees.
Organo-ID has completed 2 funding rounds, raising a total of $200.00K. The latest funding stage is Convertible Note.
Organo-ID offers: development of pre-clinical disease models, organoid technology commercialization, personalized drug testing services.
Top alternatives and competitors to Organo-ID include Emulate, Inc., Newcells Biotech (Axol Bioscience), HemoShear Therapeutics, CN Bio, MIMETAS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Organo-ID and Emulate, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Organo-ID, https://bouncewatch.com/company/organo-id, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout